However, low molecular weight (LMW) allosteric compounds targeting gonadotropin receptors have been developed for their potential to increase patient convenience in ART as these molecules would be orally available, offer a synergistic treatment with FSH for patients that respond poorly to recombinant FSH and reduce the risk of ovarian hyperstimulation syndrome, observed with high doses of recombinant gonadotropins (Nataraja et al., 2015; Anderson et al., 2018). Here, BRD2 is linked to ovarian hyperstimulation syndrome.